232 related articles for article (PubMed ID: 31127149)
1. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
3. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
4. Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia.
Yi C; He J; Huang D; Zhao Y; Zhang C; Ye X; Huang Y; Nussinov R; Zheng J; Liu M; Lu W
Cell Death Dis; 2022 Nov; 13(11):1004. PubMed ID: 36437247
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
6. ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells.
Chiou JT; Chang LS
Biochem Pharmacol; 2024 Jun; 224():116242. PubMed ID: 38679209
[TBL] [Abstract][Full Text] [Related]
7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
8. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
10. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
Chen Y; Xie X; Wu A; Wang L; Hu Y; Zhang H; Li Y
J Exp Clin Cancer Res; 2018 Jan; 37(1):12. PubMed ID: 29357910
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
12. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
Jacques S; van der Sloot AM; C Huard C; Coulombe-Huntington J; Tsao S; Tollis S; Bertomeu T; Culp EJ; Pallant D; Cook MA; Bonneil E; Thibault P; Wright GD; Tyers M
Genetics; 2020 Apr; 214(4):1103-1120. PubMed ID: 32094149
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
15. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
16. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
17. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.
Ferrarini I; Louie A; Zhou L; El-Deiry WS
Mol Cancer Ther; 2021 Sep; 20(9):1572-1583. PubMed ID: 34224362
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
19. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
Ishizawa J; Kojima K; Chachad D; Ruvolo P; Ruvolo V; Jacamo RO; Borthakur G; Mu H; Zeng Z; Tabe Y; Allen JE; Wang Z; Ma W; Lee HC; Orlowski R; Sarbassov dos D; Lorenzi PL; Huang X; Neelapu SS; McDonnell T; Miranda RN; Wang M; Kantarjian H; Konopleva M; Davis RE; Andreeff M
Sci Signal; 2016 Feb; 9(415):ra17. PubMed ID: 26884599
[TBL] [Abstract][Full Text] [Related]
20. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]